Comments on: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

Comments on: ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) https://www.worldpharmatoday.com/press-releases/ally-1-trial-results-show-investigational-daclatasvir-based-regimen-cures-94-of-post-liver-transplant-patients-with-hepatitis-c-and-up-to-94-of-hepatitis-c-patients-with-cirrhosis-child-pugh-class-a-o/ Magazine for the C-level Pharma Executives Tue, 08 Sep 2015 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4